APA (7th ed.) Citation

SD, W., X, W., YM, Z., B, H., KY, W., CJ, Y., . . . XY, Z. (2026). Setmelanotide alleviates diabetes-associated cognitive impairment by interrupting the binding of ICAM-1 and JIP1 in endothelial cells of the blood-brain barrier. Metabolism: clinical and experimental, 156712. https://doi.org/10.1016/j.metabol.2026.156712

Chicago Style (17th ed.) Citation

SD, Wu, et al. "Setmelanotide Alleviates Diabetes-associated Cognitive Impairment by Interrupting the Binding of ICAM-1 and JIP1 in Endothelial Cells of the Blood-brain Barrier." Metabolism: Clinical and Experimental 2026: 156712. https://doi.org/10.1016/j.metabol.2026.156712.

MLA (9th ed.) Citation

SD, Wu, et al. "Setmelanotide Alleviates Diabetes-associated Cognitive Impairment by Interrupting the Binding of ICAM-1 and JIP1 in Endothelial Cells of the Blood-brain Barrier." Metabolism: Clinical and Experimental, 2026, p. 156712, https://doi.org/10.1016/j.metabol.2026.156712.